Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk (TIERRA)
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00874185
First received: April 1, 2009
Last updated: February 12, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Evaluate satisfaction in people treated with IPDE5 inhibitors over time
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event. |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- EDITS [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- SEAR [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Medication prescribed [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Enrollment: | 720 |
| Study Start Date: | December 2007 |
| Study Completion Date: | May 2008 |
| Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Questionnaire
filling in questionnaires
|
Detailed Description:
12 first patients that are eligible
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
People with cv risk
Criteria
Inclusion Criteria:
- CV risk factors
- Male above 18
Exclusion Criteria:
- Non-informed consent
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00874185 History of Changes |
| Other Study ID Numbers: | A1481256, A1481256 |
| Study First Received: | April 1, 2009 |
| Last Updated: | February 12, 2013 |
| Health Authority: | Spain: Ethics Committee |
Keywords provided by Pfizer:
|
satisfaction |
Additional relevant MeSH terms:
|
Erectile Dysfunction Sexual Dysfunction, Physiological Genital Diseases, Male Sexual Dysfunctions, Psychological Sexual and Gender Disorders Mental Disorders |
Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013